. Impaired cued and spatial learning performance and altered cannabinoid CB1 receptor functionality in the substantia nigra in a rat model of diabetic neuropathy. Behavioural Brain Research, 303,[61][62][63][64][65][66][67][68][69][70] autoradiography. STZ treatment was associated with mechanical allodynia and thermal hypoalgesia. Novel object recognition was unaltered in diabetic rats. STZ treatment was associated with impaired performance in the Morris water maze acquisition phase, but there were no differences in memory retrieval in the probe trial. Stimulus-response learning in the water maze cued trial was also disrupted in STZ-treated rats, possibly indicating sensorimotor deficits. CB1 receptor agonist-stimulated [ 35 S]GTPγS binding was attenuated in the substantia nigra of STZ-treated rats but unaltered in the hippocampus. In conclusion, STZ treatment as a model of diabetic neuropathy was associated with specific functional deficits in the MWM, effects which may be related to altered CB1 receptor functionality in the substantia nigra.
Introduction
Neuropathy is a common complication of diabetes. The incidence of diabetic neuropathy is correlated positively with diabetes duration [1] , and the prevalence of painful neuropathic symptoms in diabetic patients has been estimated at ~ 34% [2] . Type 1 and type 2 diabetes are associated, to varying degrees, with cognitive deficits such as learning, memory and attentional impairments, slowing of psychomotor speed, and impaired mental flexibility [3] [4] [5] [6] [7] . Although these deficits have been well characterised, the mechanisms involved are poorly understood. Chronic pain, particularly neuropathic pain, is also associated with cognitive deficits [8, 9] . It has been proposed that pain-induced changes in neural resource utilisation, expression of neuromediators and neuroplasticity may affect cognition through a complex network of brain regions [8] . Given the prevalence of neuropathic pain in diabetes, it is possible that pain contributes to the cognitive deficits observed. This hypothesis is supported by studies reporting that a diagnosis of neuropathy was correlated with impaired cognitive performance in diabetic patients [3, 7] . A study by Ryan et al. [3] found a diagnosis of neuropathy to be the best predictor of cognitive test performance of all predictors investigated (including advanced background or proliferative retinopathy, overt nephropathy, or one or more episodes of severe hypoglycaemia). In addition, patients with diabetic neuropathy have been included in large scale studies demonstrating cognitive impairment associated with chronic pain [9] .
The streptozotocin (STZ) rodent model of diabetes has been used extensively to investigate the pathophysiology of the disease. STZ is cytotoxic to pancreatic β-cells and administration of a single high dose most closely mimics Type 1 diabetes. This model is associated with symptoms mirroring those of clinical diabetes, including altered sensitivity to thermal, mechanical and chemical noxious stimuli [10, 11] . The STZ model has also been used to investigate learning and memory impairments associated with diabetes. STZ treatment is associated with impairments in a variety of cognitive behavioural tasks such as spatial learning in the water maze [12] [13] [14] [15] , T-maze active avoidance [16] , and object-placement learning tasks [17] [18] [19] .
Learning impairments relate to the duration and severity of diabetes and to the complexity of the cognitive task [20] .
The endocannabinoid system comprises endogenous ligands, including N-arachidonoyl ethanolamide (anandamide) and 2-arachidonoylglycerol (2-AG), enzymes that biosynthesise or degrade the endocannabinoids, and two Gi/o-protein coupled receptors, cannabinoid1 (CB1) and cannabinoid2 (CB2) [21] . This system is involved in energy balance through regulation of lipid and glucose metabolism, and altered cannabinoid signalling has been associated with obesity, dyslipidaemia and type 2 diabetes [22] . A role for the endocannabinoid system in pain and analgesia is well established [23] , and cannabinoid ligands have been shown to modulate neuropathic pain, including that induced by STZ [24] . Furthermore, the endocannabinoid system mediates cognitive functions such as memory and attention, and cannabinoids have been shown to affect cognitive performance in humans [25, 26] and rodents [27, 28] . Given the involvement of the endocannabinoid system in the triad of diabetes, neuropathic pain and cognition, it represents a logical substrate for investigation in the context of cognitive impairment associated with diabetic neuropathy. [ 35 
S]GTPγS autoradiography has been used
to assess both ex vivo function and neuroanatomical distribution of Gi/o-protein-coupled CB1 receptors in discrete brain regions [29, 30] .
The aims of the present study were: (a) to investigate the development of nociceptive behaviour and cognitive performance (recognition memory and spatial learning and memory) in STZdiabetic rats and (b) to investigate the effect of STZ treatment on CB1 receptor-mediated Gprotein coupling in the hippocampus, a region classically associated with cognitive function and also implicated in pain [31, 32] , and in the substantia nigra, which is involved in movement, sensorimotor coordination, behavioural adaption based on reward or motivation, somatosensory discrimination and aspects of cognition [33] [34] [35] [36] .
Research Design and Methods

Experimental design
Male Lister-hooded rats (Charles River, UK, 225-250g) were singly-housed under standard laboratory conditions of temperature (20 ± 2°C), humidity (50-80%) and lighting (12:12 hour light/dark cycle, lights on at 08:00h), with food and water available ad libitum. Lister-hooded rats have been shown to perform well in a variety of standard tests of cognitive function including the Morris water maze [37] . Animals were singly-housed to accurately monitor food and water intake. Experiments were carried out in accordance with the guidelines and approval Figure 1 . Type 1-like diabetes was induced and blood-glucose concentrations were determined according to protocols described previously [38] . Rats received a single subcutaneous injection of 60mg/kg STZ (Sigma Aldrich Ireland) or citrate-buffer vehicle (STZ n=16, control n=16). Blood-glucose concentrations greater than 15mM were considered indicative of a diabetic phenotype.
All behavioural testing was carried out during the light phase by an experimenter blind to treatment condition and the order of testing was randomised to minimise confounding effects of time of day.
Assessment of mechanical and thermal sensitivity
Mechanical paw-withdrawal thresholds were assessed using the von Frey method described previously [39] . Testing was carried out in a six-chambered Perspex arena and animals were acclimatised to the arena prior to testing. Measurement of withdrawal thresholds involved mechanical stimulation of the hind paws with von Frey filaments (Touch-Test ™ Sensory Evaluators, North Coast Medical, Inc.) of differing weights (1.4g to 12g), and a positive response was recorded if flinching, licking or withdrawal of the paw was observed. The 50% response threshold was calculated for each hind paw and a mean response threshold for each rat was computed as the mean of the two hind paws.
Thermal nociceptive responses were assessed using a protocol similar to that described previously [39] . A commercial instrument (Plantar/tail flick combination system, model 336, IITC Life Science Inc., USA) was used, and animals were habituated to the arena prior to testing. The thermal stimulus was applied until a positive response (criteria similar to von Frey testing) was recorded or until a cut-off time of 20s was reached. The mean withdrawal latency for each rat was computed from the applications to both hind paws (four/paw).
Assessment of cognitive function
Novel-object recognition
The procedure used for the novel-object recognition test was similar to that previously described by King et al. [40] , with some modifications. The apparatus was constructed of Perspex and melamine-coated chipboard (60cm x 30cm x 40cm). The "familiar" objects used were two plastic bottles covered with white masking tape. A third bottle, the "novel object" had three strips of black tape, making it visually distinct. Animals were habituated to the arena in the absence of objects for 30 minutes on the day before the test day. The test day comprised three stages: habituation (3min exposure to arena in absence of objects), exposure 1 (3min familiarisation to identical objects) and exposure 2 (3min exposure to one familiar and one novel object). Habituation and exposure 1 were separated by a 7min inter-trial interval and exposures 1 and 2 by a further 2min interval. Exploration of an object was defined as described previously [41] . The three test stages were recorded to videotape for subsequent analysis.
Object exploration and general behaviours (sniffing, rearing, walking) were manually rated using Ethovision® software (Noldus, The Netherlands), and the discrimination ratio for each object was calculated as (time spent exploring either object)/(time spent exploring both objects).
Morris Water Maze (MWM)
Procedures for water-maze acquisition training, probe trial and cued test were similar to those described previously [42] . The apparatus consisted of a circular black plastic pool (95cm diameter) with a white plastic platform (11cm x 43cm). Visual cues were placed around the outside of the maze during acquisition training and during probe trials. For acquisition training, the pool was filled to 2cm above the level of the platform and the water was made opaque (by addition of white paint, Icon Apprentice, Ireland), such that the platform was hidden. The training consisted of four trials per day for five days, throughout which the platform was positioned in the southwest quadrant of the pool. Animals were released from one of four release points in a quasi-random order, and were given 120s to locate the hidden platform.
Once the platform was successfully located, the rat was allowed to remain on the platform for 10s. If the rat did not locate the platform within 120s, it was guided towards it by the experimenter. The animal was then removed from the pool, dried and placed in a heated recovery cage for an inter-trial period (5-15min). A probe trial was carried out on the day after acquisition training was completed. The platform was removed from the maze, and rats were released from the northeast quadrant. The probe trial consisted of a single 60s trial for each rat.
The cued test was conducted the day after probe trial and each rat underwent six trials. The water level was reduced to 2cm below the height of the platform so that the platform was visible. The procedure was similar to that for acquisition, except the platform was moved to a different quadrant between trials. All trials were recorded to videotape; post testing, Ethovision® software was used to measure the following parameters: distance moved (path length) to locate the platform for acquisition training and cued test, distance moved in each of the arena zones (platform, annulus, and southeast, southwest, northeast and northwest quadrants) and swim speed for the probe trial.
[
S]GTPγS autoradiography
Animals were killed by decapitation on day 46 post-STZ injection. Brains were removed, snapfrozen on dry ice and stored at -80°C until sectioning. A subset of the brains from control and STZ-treated rats were chosen randomly for slides were removed and rinsed twice in ice-cold TRIS buffer (pH 7.4) followed by a further 3 x 2min washes in ice-cold TRIS buffer. Slides were then dipped in distilled, deionised H2O and dried in a warm air stream before exposure to Hyperfilm-β max autoradiographic film (GE Healthcare, UK) for a minimum of 48 hours. Films were developed by hand using Kodak GBX developer and fixer (Kodak, UK). Autoradiograms were digitised using an Epson Perfection 4870 Photo scanner, and resulting images were analysed densitometrically using ImageJ software for PC. A standard curve relating greyscale density to disintegrations per minute (DPM) was constructed using 14 C microscale standards which had been exposed alongside the samples. The dorsal hippocampus (CA1-3 and dentate gyrus) and substantia nigra were then outlined with reference to the rat brain atlas [43] , and measured greyscale values were converted to DPM.
Statistical Analysis
Behavioural data were analysed by repeated-measures or one-way analyses of variance (ANOVA), with the exception of probe-trial data which were analysed by Student's unpaired two-tailed t tests (for individual arena zones and distance moved). 
Results
Induction of diabetes following STZ injection
The effects of STZ administration on body weight, water intake and blood glucose are shown in Figure 2 . Two-way repeated-measures ANOVA revealed significant effects of time = 8502, p < 0.0001), and a treatment x time interaction (F(4,112) = 484.6, p < 0.0001) on blood glucose concentrations. Blood glucose concentrations were significantly increased from 3 days post-STZ injection and remained elevated throughout the experiment, confirming development of a diabetic phenotype. All STZ-treated rats developed hyperglycaemia and two animals were excluded due to ill health.
Development of mechanical allodynia following STZ injection
von Frey testing for mechanical allodynia was performed on days 4, 6, 10, 17, 19, 23 and 26
post-STZ injection and baseline measures were taken two days pre-STZ injection. There were no differences between the two groups at baseline (Figure 3 ). Two-way repeated-measures ANOVA revealed a significant main effect of time (F(7,175) = 9.124, p < 0.0001) and an interaction effect (treatment x time; F(7,175) = 2.500, p = 0.0180). In the STZ-treated group, hind paw 50% withdrawal threshold was significantly decreased at all post-injection time points compared with baseline ( Figure 3 ). There was also a decrease in threshold in the control group relative to baseline at a number of discrete post-injection time points (days 4, 10, 17 and 26, Figure 3 ). The 50% withdrawal threshold was significantly lower in STZ-diabetic animals compared with controls on days 19 and 23 post-STZ injection, indicating development of mechanical allodynia in the STZ-treated rats ( Figure 3 ). Three animals were excluded for von
Frey analysis due to missing values in the timecourse of mechanical threshold measurements.
Hargreaves test for thermal sensitivity
Hargreaves testing was carried out one day before STZ or control injection (baseline), and on 
Novel object recognition (NOR)
STZ treatment had no effect on general exploratory behaviours (sniffing and walking) during the habituation period on the test day ( Figure 5(a) ), but STZ-treated animals did show significantly reduced rearing compared with control animals. Discrimination ratios were calculated both for the identical objects in exposure 1 and for the novel and familiar objects in exposure 2. During exposure 1, both objects were explored equally, and there were no betweengroup differences (data not shown). During exposure 2, the discrimination ratio for the novel object was significantly greater than that for the familiar object in both control and STZ-treated animals, indicating a preference for the novel object in both groups ( Figure 5(b) ). Data were analysed by a one-way ANOVA (F(3.51) = 10.57, p<0.001) followed by Fisher's LSD post hoc tests. There were no significant between-group differences. Together, these results suggest that STZ treatment is associated with a specific deficit in MWM acquisition learning, but not memory retrieval, and with motor and sensorimotor impairments. (Figure 7(a) ). Dorsal and ventral hippocampal regions and dentate gyrus were also analysed separately and no significant between-group differences were observed (data not shown).
Morris water maze (MWM)
Two
[ 35 S]GTPγS binding autoradiography
In the substantia nigra, two-way ANOVA revealed significant main effects of drug (Figure 7(b) ). Representative autoradiograms from sections containing the substantia nigra are presented in Figure 8 .
Discussion
The results presented herein confirm that administration of streptozotocin induces a diabetic phenotype, characterised by increased blood-glucose concentration, reduced weight gain and increased water intake. Mechanical allodynia developed over time relative to baseline, and mechanical threshold was significantly lower in STZ-treated rats compared with controls on days 19 and 23 post treatment. Thermal hypoalgesia was also observed in STZ-diabetic animals. Recognition memory in the novel object recognition paradigm was not impaired in STZ-treated animals. Furthermore, non-object-directed exploratory behaviour (sniffing) was not affected by STZ treatment. There was, however, a significant reduction in rearing in STZtreated rats compared with controls. In MWM acquisition, STZ-treated rats showed a deficit in spatial learning. STZ treatment was also associated with motor and sensorimotor impairments, but not with adverse effects on memory-retrieval. CB1 receptor functionality in the hippocampus was not altered in STZ-diabetic animals, but was significantly lower in the substantia nigra of STZ-treated compared with controls.
The development of tactile allodynia/mechanical hyperalgesia in the STZ model of diabetes is well documented in the literature [10, 11, 38] and is consistent with the present results. Studies show signs of reduced mechanical/tactile thresholds within 1-2 weeks post induction of diabetes that further reduce with time [10, 44, 45] . Changes in mechanical threshold compared with baseline were also observed in the saline-treated animals at discrete time points, possibly due to sensitisation of the hind paws over time. This is consistent with the observation by Chaplan at al. [46] that repetitive low-intensity stimulation with von Frey filaments of the hind paw of naïve rats was associated with a gradual decrease in mechanical response threshold.
This is presumed to be adaption of behaviour in response to "annoyance or nuisance in the absence of nociception". Nevertheless, the STZ-treated group showed greater sensitivity to mechanical stimuli than the saline-treated group overall; confirming that induction of diabetes produced the expected neuropathic pain-like phenotype. STZ-treated rodents show varying responses to thermal stimuli, including hypoalgesia, hyperalgesia, no alteration of response, and initial hyperalgesia followed by hypoalgesia or a return to control levels [38] . The reasons for these conflicting results are unclear but possible explanations include methodological differences e.g. the specific location of the heat-stimulus application, the time of testing post STZ administration, and species and strain differences in behavioural pain testing [38] . It is important to note that the between-group difference in paw-withdrawal latency is relatively small (mean difference < 2s). Hypoalgesia reported by Rutledge et al. [47] represented an average change in response latency of up to 7.6s. However, STZ-induced hyperalgesia with an average change in response latency of approximately 2s has been reported previously [38, 48] under similar experimental conditions to the present study. No significant time effect was observed in the present study, suggesting that thermal sensitivity was not altered post STZ compared with baseline.
We found no effect of STZ treatment on recognition memory in the novel-object recognition task. Interestingly, some previous findings of impaired recognition memory in the STZ model were based on object-placement/spatial-recognition paradigms, rather than on the commonly used object-recognition paradigm employed in the present study [49] [50] [51] . This methodological difference may explain the lack of any STZ-induced effect in the present study. In a spatial/object learning and memory paradigm, Popovic et al. [17] found that increasing task complexity was negatively correlated with task performance. Therefore, the novel-object paradigm used herein may not have been sufficiently complex to detect differences between STZ-treated and control rats.
We found that STZ treatment was associated with a deficit in MWM acquisition, as path length to the hidden platform was longer for STZ-treated animals than for control rats. This is in line with previous studies investigating water-maze performance in STZ-diabetic rats [12] [13] [14] 52 ].
Measurement of path length (distance swam to get onto the platform) controls for the potential confound of motor impairment in the MWM, and therefore the present findings suggest that the deficits observed in STZ-treated rats are specifically related to cognitive impairment. The impairment also appears to be specific to spatial learning, as there were no between-group differences in the probe trial which predominately assesses memory retrieval.
Biessels et al. [12] demonstrated that deficits in water-maze performance were not observed if animals are given non-spatial pre-training, and suggested that STZ-induced effects did not equate to impaired spatial learning but rather to impaired learning of the maze procedure itself, i.e., diabetic animals fail to learn that the platform is the quickest route of escape. In the present study, animals that failed to learn to use the platform as an escape route (based on cued-trial performance) were excluded from the MWM acquisition and probe-trial results. Notably, this exclusion criterion applied to five STZ-treated rats (36% of subjects) and to no control rats. In the cued trial itself, the STZ-treated group took a significantly longer path to the visible platform than did the control group. This suggests that even though they associated the platform with escape, STZ-treated animals still failed to grasp the primary goal of the cued task, which may be due to a deficit in sensorimotor integration, i.e., coordinating visualisation of the platform and the objective of swimming to it.
We hypothesised that impaired cognitive function in STZ-treated rats may be associated with reduced functionality of cannabinoid receptors in the hippocampus. This was based on the involvement of the endogenous cannabinoid system in pain, particularly neuropathic pain [22, 23] , and in cognition [25] [26] [27] [28] . It has been suggested that pain-related alterations in neurotransmitter systems, including the endocannabinoid system, may mediate the cognitive deficits observed in neuropathic pain in animals and humans [8] , and this may extend to deficits associated with painful diabetic neuropathy. To our knowledge, cannabinoid-induced Gprotein coupling has not been investigated previously in an animal model of diabetic neuropathy.
Our results suggest that cannabinoid agonist-stimulated [
S]GTPγS binding in the
hippocampus is unaffected by STZ administration. This finding does not preclude the involvement of the hippocampal cannabinoid system in STZ-related deficits in the water maze, but may be due to methodological issues such as the time post STZ at which animals were sacrificed. It is also possible that cannabinoid receptor functionality was altered in other cognition-related brain regions that were not investigated in the present study. Neuropathic pain is believed to negatively affect executive functions mediated by the prefrontal cortex [8] .
Reversal tasks in the Morris water maze assess cognitive flexibility (analogous to human executive functions) and future studies should investigate the effects of STZ treatment on reversal learning and the cannabinoid system in the prefrontal cortex.
There was a significant difference between STZ and control rats for HU210-stimulated
GTPγS binding in the substantia nigra. Given the behavioural results observed, the altered cannabinoid functionality in this region may be of particular interest. The substantia nigra is a midbrain structure and a component of the basal ganglia. The role of the substantia nigra in movement is well established, and it is also associated with sensorimotor coordination, behavioural adaption based on reward or motivation, somatosensory discrimination, visual perception, spatial working memory and habit learning [33] [34] [35] [36] . The substantia nigra pars reticulata contains spontaneously active GABAergic neurons [53] which tonically inhibit movement. Cannabinoid-mediated disinhibition of GABAergic tone would therefore facilitate movement, and a decrease in CB1 receptor functionality could be associated with impaired motor function. Such a mechanism may underlie the decrease in distance moved in the probe trial, and the reduced rearing behaviour observed in the present study. While the standard placelearning MWM task is thought to be hippocampal-dependent, the cued test requires stimulusresponse learning and recent evidence has shown that cued-test performance is disrupted by lesion of the substantia nigra [54, 55] . Thus, the finding of impaired functionality of cannabinoid receptors in the substantia nigra in this study may be a contributory factor in the impaired cued-test learning in the STZ-treated animals. Future studies should involve manipulation of the cannabinoid system in the substantia nigra in the STZ model to determine whether deficits in cued learning can be reversed.
In conclusion, STZ-diabetic rats showed impairments in cognitive function in both the cuedand spatial-learning tasks of the MWM. These behavioural observations were accompanied by altered cannabinoid receptor functionality in the substantia nigra. Further investigation is warranted to determine whether and how the endocannabinoid system in the substantia nigra mediates STZ-induced alterations in water-maze behaviour. 
